Currently, KIF23 [74,75] and KIF11 [78] are under investigation as TNBC drug targets; KIF11 inhibition was previously shown to stall the tumor growth of breast cancer xenografts [77], while KIF23 drove TNBC migration, proliferation, and the metastasis-promoting epithelial–mesenchymal transition in vitro [74,75]. Here, KIF23 is linked to neoplasm.